LUPUS NEPHRITIS - WHO CLASS III
Clinical trials for LUPUS NEPHRITIS - WHO CLASS III explained in plain language.
Never miss a new study
Get alerted when new LUPUS NEPHRITIS - WHO CLASS III trials appear
Sign up with your email to follow new studies for LUPUS NEPHRITIS - WHO CLASS III, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Experimental cell therapy trial offers hope for Tough-to-Treat lupus
Disease control OngoingThis early-stage trial is testing a new cell therapy called AB-101 for adults with severe lupus nephritis or other hard-to-treat forms of lupus who haven't responded to standard treatments. AB-101 is made from donated natural killer (NK) cells, a type of immune cell, and is given…
Matched conditions: LUPUS NEPHRITIS - WHO CLASS III
Phase: PHASE1 • Sponsor: Artiva Biotherapeutics, Inc. • Aim: Disease control
Last updated Apr 03, 2026 14:41 UTC
-
Groundbreaking cell therapy trial targets devastating lupus kidney damage
Disease control OngoingThis early-stage study is testing a new, personalized cell therapy called KYV-101 for adults with severe lupus nephritis, a serious kidney disease caused by lupus, that hasn't responded to other treatments. The therapy involves modifying a patient's own immune cells to target and…
Matched conditions: LUPUS NEPHRITIS - WHO CLASS III
Phase: PHASE1, PHASE2 • Sponsor: Kyverna Therapeutics • Aim: Disease control
Last updated Mar 23, 2026 15:15 UTC